Adipose tissue binding, 130
Adverse drug reaction, 320
Ah receptor, 342
Analytical, 54, 55, 67, 68, 69, 71, 73, 81, 96, 115, 116, 139, 140, 141,144, 195, 219, 235, 236, 248, 249, 265, 273, 274, 277, 296, 335, 336
Aryl hydrocarbon receptor, 210
Benzo[a]pyrene, 61, 210
Bioactivation, 143, 293
Bioavailability, 54, 61, 119, 121, 169, 324, 334, 336
Biotransformation, 123, 281, 282
Blood-Brain Barrier, 247
C57BL/6 Substrains, 220
Chiral, 73
Circulating metabolites, 146
Clearance prediction, 55, 58, 75, 77, 80, 106, 110, 223, 225, 266, 302, 316, 332, 350, 358
CNS activity, 134
CNS Drugs, 97
Conjugation reactions and enzymes, 71, 74, 78, 79, 82, 83, 84, 85, 155, 186, 191, 194, 200, 203, 218, 240, 241, 258, 264, 275, 277, 280, 305
Covalent binding, 256
CYP2C9, 89
CYP2D6-humanized mouse, 170, 278
CYP2E1, 118
CYP3A4, 90
Cytochrome P450, 54, 55, 61, 64, 70, 74, 81, 86, 87, 88, 91, 92, 94, 96, 97, 100, 101, 103, 104, 105, 107, 109, 110, 112, 113, 114, 118, 120, 121, 122, 125, 126, 128, 129, 145, 146, 147, 148, 149, 150, 151, 152, 157, 159, 163, 164, 165, 168, 169, 171, 172, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 188, 189, 190, 192, 193, 196, 197, 198, 199, 201, 204, 205, 212, 215, 216, 220, 223, 221, 225, 233, 235, 236, 238, 250, 251, 258, 263, 279, 280, 289, 292, 293, 298, 303, 304, 312, 313, 322 , 323, 328, 337
Data mining, 252
Decision support, 244
Desipramine, 278
Differences in metabolism (species, gender, age, diseases), 55, 56, 83, 86, 104, 120, 122, 124, 125, 127, 128, 138, 172, 175, 183, 201, 220, 230, 261, 262, 266, 269, 282, 284, 295, 306, 324, 350
Disposition, 77, 111, 119, 121, 123, 124, 127, 130, 131, 133, 136, 140, 145, 168, 194, 198, 214, 218, 248, 281, 282, 291, 301, 311, 326, 328, 329, 335, 349, 354, 356, 364, 365, 366
Dog recombinant CYP, 91
Drug discovery and development, 56, 71, 72, 75, 77, 78, 81, 95, 96, 102, 124, 126, 129, 130, 134, 135, 138, 139, 141, 143, 144, 150, 151, 157, 165, 181, 189, 190, 219, 225, 227, 228, 230, 232, 238, 240, 241, 242, 244, 245, 249, 250, 251, 253, 254, 257, 265, 271, 272, 284, 286, 287, 291, 292, 293, 301, 303, 326, 327, 329, 330, 331, 332, 338, 347, 349, 352, 354, 357, 364, 366, 369
Drug interaction, 80, 85, 97, 102, 105, 111, 147, 149, 150, 151, 152, 153, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 166, 167, 169, 172, 177, 178, 180, 184, 185, 186, 188, 189, 195, 197, 198, 199, 200, 205, 224, 233, 234, 237, 238, 243, 253, 255, 264, 341, 348, 349, 353, 354, 355, 356, 361, 362, 364, 374
Drug safety, 243
Efavirenz, 145
Efflux, 247, 360
Enzyme induction, 59, 62, 86, 99, 105, 112, 164, 165, 171, 172, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 204, 213, 215, 216, 230, 231, 305, 341, 342, 361
Enzyme inhibition/inactivation, 85, 95, 99, 110, 112, 115, 145, 146, 147, 148, 149, 150, 151, 152, 155, 156, 157, 159, 163, 164, 169, 179, 184, 185, 186, 188, 189, 191, 193, 196, 198, 199, 200, 203, 224, 233, 234, 238, 237, 243, 264, 279, 292, 358
Enzyme kinetics, 196
Epigenetic, 211, 207
ER associated degradation, 107
Esterase, 306
Estrogen, 98
Excipient, 212
Extrahepatic metabolism, 61, 74, 95, 111, 202, 203, 204, 213, 221, 263, 283, 371
FMO1, 309
Gastroparesis, 159
Gene expression and regulation, 53, 57, 60, 62, 64, 84, 86, 93, 98, 109, 112, 171, 173, 182, 183, 187, 204, 205, 206, 207, 208, 210, 211, 214, 215, 217, 218, 219, 221, 224, 230, 231, 314, 322, 339, 341, 342, 344, 351, 371, 374
Genomics/Metabonomics/Proteomics, 53, 221, 265, 316, 318, 320
Gstm1-null mice, 174
Hepatocytes, 53, 72, 77, 98, 105, 107, 118, 142, 161, 171, 172, 175, 176, 177, 178, 179, 180, 181, 185, 186, 193, 209, 222, 223, 224, 225, 226, 227, 228, 229, 231, 250, 251, 254, 261, 271, 302, 303, 305, 318, 353, 357, 356, 358, 364, 369
Hepatotoxicity, 137
High resolution, 96
High throughput techniques, 53, 66, 71, 97, 99, 105, 129, 142, 177, 232, 233, 234, 235, 237, 239, 242, 244, 252, 255, 275
Hypoxia, 338
Imaging, 366
Iminium ions, 260
In Silico, 79, 115, 134, 148, 167, 168, 203, 239, 240, 241, 242, 244, 245, 252, 298, 328, 338, 358, 372
In vitro techniques, 60, 70, 71, 78, 80, 81, 89, 90, 92, 97, 99, 108, 102, 110, 113, 128, 131, 139, 141, 149, 150, 151, 153, 155, 161, 165, 169, 179, 184, 185, 189, 190, 191, 192, 193, 195, 201, 219, 222, 226, 227, 229, 233, 236, 237, 238, 246, 247, 248, 252, 254, 255, 257, 269, 272,275, 277, 286, 287, 289, 290, 302, 305, 310, 321, 335, 346, 348, 349, 350, 353, 354, 352, 355, 356, 357, 358, 360, 361, 362
Inflammation, 263
Intestinal first-pass metabolism, 58
Isoxazole, 307
Jurkat, 210
Kinetics, 108
LC/MS/MS Bioanalysis, 69
Mechanisms of xenobiotic toxicities, 61, 64, 143, 152, 158, 187, 342, 261, 204, 220, 253, 240, 241, 251, 252, 255, 257, 259, 260, 262, 279, 297, 305, 343
Metabolic profiling, 66, 67, 68, 70, 72, 88, 119, 123, 124, 127, 136, 139, 140, 141, 142, 143, 144, 152, 195, 235, 236, 239, 242, 258, 264, 265, 266, 267, 268, 270, 272, 273, 274, 275, 276, 277, 279, 281, 282, 283, 284, 286, 287, 291, 292, 295, 298, 301, 302, 304, 308, 318, 326
Metabolism, 59, 65, 68, 70, 72, 79, 80, 83, 87, 88, 90, 94, 95, 96, 98, 100, 102, 104, 106, 111, 113, 115, 120, 121, 123, 124, 126, 128, 136, 137, 140, 141, 142, 144, 145, 148, 156, 157, 163, 164, 165, 170, 175, 184, 187, 195, 197, 199, 201, 202, 203, 206, 213, 223, 224, 225, 228, 231, 235, 236, 239, 240, 241, 242, 249, 250, 251, 257, 258, 259, 261, 264, 266, 269, 270, 271, 272, 273, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 291, 292, 294, 299, 301, 304, 306, 307, 308, 309, 311, 315, 318, 321, 322, 323, 326, 328, 336, 341, 357, 374
Metabolite identification, 303
Metabolite Quantification, 276
MicroRNA, 109, 205, 214
miRNA, 351
Modeling, 333
Monoamine oxidase, 311
Nanotechnology, 131
Nicotine, 100
NMR, 102
Non-P450 phase I enzymes, 127, 136, 201, 202, 213, 223, 280, 286, 287, 307, 309, 310, 311, 315
Nrf2, 216
Oxygen consumption, 297
Passive Diffusion, 247
Pathways, 299
PBPK, 168
P-Glycorpotein, 367
Pharmacogenetics, 55, 62, 65, 89, 148, 170, 198, 220, 262, 312, 313, 314, 316, 317, 318, 319, 321, 322, 337, 370, 374
Pharmacokinetics, 357
Pharmacokinetics and Pharmacodynamics, 54, 56, 57, 75, 79, 88, 113, 121, 131, 133, 135, 143, 163, 168, 170, 245, 247, 248, 265, 266, 269, 271, 273, 276, 301, 314, 316, 324, 326, 327, 328, 329, 330, 331, 332, 334, 337, 338, 350, 356, 366
Phase 2 metabolism, 290
Phenotyping, 289
Plasma, 192
Plasma Stability Assay, 138
POR, 323
Proguanil, 145
Protein binding, 249
Protein-protein interactions, 110
Quantitative and Qualitative Analysis, 142
Reaction phenotyping, 92
Reactive Drug Metabolite, 275
Reactive intermediates, 81
Reactive metabolites, 257
Receptors/nuclear receptors, 53, 62, 64, 109, 153, 181, 182, 206, 209, 210, 213, 216, 217, 218, 340, 341, 342, 343, 344, 345, 346, 371
Regioselectivity, 298
Sarpogrelate, 334
Sensitvity increase with DynamicFlow, 274
Sickle cell, 322
Signal transduction, 161
Statin, 370
Stereoselective metabolism, 82
Structural elucidation, 271
Sulfotransferase, 83
Suppression, 215
Tight Junctions, 247
Tissue and sample preparation, 219
Tissue Binding, Protein Binding, 248
Toxicity, 208
Transcription regulation, 64
Transporters, 56, 57, 63, 64, 74, 76, 77, 154, 156, 158, 171, 180, 205, 206, 214, 218, 222, 226, 229, 231, 245, 247, 347, 348, 349, 350, 351, 352, 353, 354, 355, 359, 360, 363, 364, 365, 366, 367, 369, 370, 372, 373
UDP-Glucuronosyltransferases, 80
UGT enzymes, 191, 246
Warfarin, 82
Yeast, 101